QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
47.57 USD
-0.81 (-1.67%)
47.57 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to QGEN. QGEN was compared to 57 industry peers in the Life Sciences Tools & Services industry. QGEN scores excellent points on both the profitability and health parts. This is a solid base for a good stock. QGEN has a decent growth rate and is not valued too expensively. This makes QGEN very considerable for quality investing!
1. Profitability
1.1 Basic Checks
- QGEN had positive earnings in the past year.
- QGEN had a positive operating cash flow in the past year.
- In the past 5 years QGEN has always been profitable.
- Each year in the past 5 years QGEN had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 6.19%, QGEN belongs to the best of the industry, outperforming 82.46% of the companies in the same industry.
- With an excellent Return On Equity value of 11.11%, QGEN belongs to the best of the industry, outperforming 82.46% of the companies in the same industry.
- QGEN has a better Return On Invested Capital (7.44%) than 78.95% of its industry peers.
- QGEN had an Average Return On Invested Capital over the past 3 years of 7.25%. This is significantly below the industry average of 13.75%.
- The last Return On Invested Capital (7.44%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
- Looking at the Profit Margin, with a value of 19.58%, QGEN belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.
- QGEN's Profit Margin has declined in the last couple of years.
- QGEN's Operating Margin of 27.02% is amongst the best of the industry. QGEN outperforms 96.49% of its industry peers.
- QGEN's Operating Margin has improved in the last couple of years.
- The Gross Margin of QGEN (64.10%) is better than 85.96% of its industry peers.
- In the last couple of years the Gross Margin of QGEN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
- QGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, QGEN has less shares outstanding
- The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
- QGEN has a better debt/assets ratio than last year.
2.2 Solvency
- QGEN has an Altman-Z score of 3.62. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
- QGEN has a Altman-Z score of 3.62. This is in the better half of the industry: QGEN outperforms 70.18% of its industry peers.
- The Debt to FCF ratio of QGEN is 4.50, which is a neutral value as it means it would take QGEN, 4.50 years of fcf income to pay off all of its debts.
- QGEN has a better Debt to FCF ratio (4.50) than 73.68% of its industry peers.
- A Debt/Equity ratio of 0.45 indicates that QGEN is not too dependend on debt financing.
- QGEN has a Debt to Equity ratio of 0.45. This is in the lower half of the industry: QGEN underperforms 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.62 |
ROIC/WACC0.89
WACC8.36%
2.3 Liquidity
- A Current Ratio of 2.60 indicates that QGEN has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 2.60, QGEN is in line with its industry, outperforming 49.12% of the companies in the same industry.
- A Quick Ratio of 2.30 indicates that QGEN has no problem at all paying its short term obligations.
- QGEN's Quick ratio of 2.30 is in line compared to the rest of the industry. QGEN outperforms 52.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
- QGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.18%, which is quite good.
- Measured over the past 5 years, QGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.92% on average per year.
- Looking at the last year, QGEN shows a small growth in Revenue. The Revenue has grown by 5.32% in the last year.
- QGEN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.32% yearly.
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
- The Earnings Per Share is expected to grow by 9.41% on average over the next years. This is quite good.
- The Revenue is expected to grow by 7.12% on average over the next years.
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 20.07 indicates a rather expensive valuation of QGEN.
- Compared to the rest of the industry, the Price/Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 92.98% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.47, QGEN is valued a bit cheaper.
- A Price/Forward Earnings ratio of 18.36 indicates a rather expensive valuation of QGEN.
- Based on the Price/Forward Earnings ratio, QGEN is valued cheaper than 92.98% of the companies in the same industry.
- QGEN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.26, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.07 | ||
| Fwd PE | 18.36 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 92.98% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, QGEN is valued cheaply inside the industry as 85.96% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.83 | ||
| EV/EBITDA | 14.14 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
- The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.58
PEG (5Y)2.53
EPS Next 2Y7.68%
EPS Next 3Y8.33%
5. Dividend
5.1 Amount
- With a yearly dividend of 0.54%, QGEN is not a good candidate for dividend investing.
- QGEN's Dividend Yield is rather good when compared to the industry average which is at 0.09. QGEN pays more dividend than 94.74% of the companies in the same industry.
- With a Dividend Yield of 0.54, QGEN pays less dividend than the S&P500 average, which is at 1.89.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
5.2 History
- QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y7.68%
EPS Next 3Y8.33%
47.57
-0.81 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2025-11-04/dmh
Earnings (Next)02-03 2026-02-03/amc
Inst Owners85.46%
Inst Owner Change-0.39%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.32B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts72.5
Price TargetN/A
Short Float %3.17%
Short Ratio5.75
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.54% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-0.39%
PT rev (3m)-1.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.96%
EPS NY rev (1m)-0.77%
EPS NY rev (3m)-0.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.07 | ||
| Fwd PE | 18.36 | ||
| P/S | 4.98 | ||
| P/FCF | 21.83 | ||
| P/OCF | 15.68 | ||
| P/B | 2.83 | ||
| P/tB | 12.93 | ||
| EV/EBITDA | 14.14 |
EPS(TTM)2.37
EY4.98%
EPS(NY)2.59
Fwd EY5.45%
FCF(TTM)2.18
FCFY4.58%
OCF(TTM)3.03
OCFY6.38%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.58
PEG (5Y)2.53
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.62 |
F-Score8
WACC8.36%
ROIC/WACC0.89
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)8.18%
EPS 3Y-7.35%
EPS 5Y7.92%
EPS Q2Q%4.04%
EPS Next Y7.77%
EPS Next 2Y7.68%
EPS Next 3Y8.33%
EPS Next 5Y9.41%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year4.96%
Revenue Next 2Y5.54%
Revenue Next 3Y5.79%
Revenue Next 5Y7.12%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.21%
EBIT Next 3Y22.16%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
Can you provide the valuation status for QIAGEN N.V.?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What is the earnings growth outlook for QIAGEN N.V.?
The Earnings per Share (EPS) of QIAGEN N.V. (QGEN) is expected to grow by 7.77% in the next year.